Mostrar registro simples

dc.contributor.authorColet, Christiane de Fátimapt_BR
dc.contributor.authorAmador, Tania Alvespt_BR
dc.contributor.authorHeineck, Isabelapt_BR
dc.date.accessioned2020-01-16T04:10:24Zpt_BR
dc.date.issued2019pt_BR
dc.identifier.issn2359-4802pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/204377pt_BR
dc.description.abstractBackground: Warfarin is an oral anticoagulant involved in important interactions with foods and other drugs. Objectives: To evaluate the occurrence of adverse events reported by warfarin users and their relationship with drug interactions. Methods: This was an open cohort, prospective study conducted in an 18-month period with warfarin users attending public health clinics of the city of Ijuí, Brazil. Data were collected by means of interviews administered at patients’ home every month. Patients’ responses were confirmed by review of medical records when patients sought medical care. Data were analyzed by descriptive statistics. Potential drug interactions were evaluated in a database and vitamin K consumption was quantified using a validated method. Results: A total of 68 patients were followed-up; 63 completed the study and 5 died in the study period. Mean number of medications taken by the patients was 9.6 ± 4.5, and mean number of interactions involving warfarin was 2.91 ± 1.52. Most potential interactions increased the risk of bleeding, 61 of them severe interactions and 116 moderate interactions. Eighty-seven episodes of bleeding and 4 episodes of thrombosis were reported by a total of 37 and 4 patients, respectively. At the occurrence of these events, 56.5% of warfarin users were also taking omeprazole, 35.9% were taking simvastatin and 25.0% paracetamol. Most patients had a low vitamin K intake. Conclusions: A high frequency of potential interactions between warfarin and other drugs was detected, but a low intake of foods that could possibly affect the effects of warfarin was observed. Based on our results, it seems prudent to follow patients on warfarin therapy for drug-drug interactions, aiming to control adverse effects and to promote a safe and effective therapy.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofInternational Journal of Cardiovascular Sciences. São Paulo (SP). Vol. 32, no. 2 (Mar./Abr. 2019), p. 110-117pt_BR
dc.rightsOpen Accessen
dc.subjectAnticoagulants/adverse effectsen
dc.subjectFarmáciapt_BR
dc.subjectWarfarinen
dc.subjectAnticoagulantespt_BR
dc.subjectVarfarinapt_BR
dc.subjectPharmacovigilanceen
dc.subjectDrug interactionsen
dc.subjectFarmacovigilânciapt_BR
dc.subjectInterações de medicamentospt_BR
dc.subjectDrug incompatibilityen
dc.subjectIncompatibilidade de medicamentospt_BR
dc.subjectOmeprazoleen
dc.subjectSimvastatinen
dc.subjectOmeprazolpt_BR
dc.subjectSinvastatinapt_BR
dc.subjectAcetaminophenen
dc.subjectVitamin Ken
dc.subjectAcetaminofenpt_BR
dc.subjectDelivery health care/statistics & numeral dataen
dc.titleDrug interactions and adverse events in a cohort of warfarin users attending public health clinicspt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001109107pt_BR
dc.type.originNacionalpt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples